The Prompt Approval of Safe Generic Drugs Act would amend federal drug approval rules to allow generic and biosimilar drugs to gain FDA approval more quickly even when they cannot include certain safety information on their labels. Currently, generic drugs cannot be approved if they omit safety details that are protected by the brand-name drug's patent or exclusivity rights. This bill would change that by requiring the FDA to approve generic versions while still ensuring they carry appropriate safety warnings deemed necessary by the FDA. The legislation primarily affects generic drug manufacturers and patients who use generic medications, potentially making these drugs available sooner and at lower costs. The bill does not appear to include specific funding allocations or implementation timelines, instead focusing on changing the regulatory standards the FDA must apply when reviewing generic drug applications.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.